Exhibit 99.1
Aug. 9, 2010
GenMark Reports Second Quarter Results
Revenues Increase 162% over Prior Year
System Placements Increase by Twelve to Twenty Year-to-Date
Dr. Jon Faiz Kayyem appointed Chief Scientific Officer
Christopher Gleeson appointed Interim CEO
CARLSBAD, Calif.—(BUSINESS WIRE)—GenMark Diagnostics, Inc. (Nasdaq:GNMK) today reported revenues of $651,000 for the quarter ending June 30, 2010, a 162% increase over second quarter 2009. Net loss for the second quarter was $5.1 million, or $0.60 per share, compared to a net loss of $4.3 million and $1.08 per share for the same period last year.
Reagent test revenues of $415,000 were 80% higher than the second quarter of 2009, while instrument revenues were $108,000 versus zero for the comparable prior year period. Total revenues included $100,000 associated with a non recurring partnering contract for clinical trial support. Gross margin loss of $212,000 for the current quarter was a 56% improvement compared to the $484,000 gross margin loss for 2009. Investment in R&D increased $291,000, up 20% over the prior year quarter and investment in commercial activities, primarily related to sales force expansion, was up $462,000 or 62% over the prior year quarter.
Consistent with GenMark’s key strategic initiatives associated with product development, the Board of Directors announced the appointment, effective August 12, 2010, of Dr. Jon Faiz Kayyem, the current President and Chief Executive Officer (CEO), to the newly established position of Chief Scientific Officer (CSO). In this capacity, Dr. Kayyem will oversee all activities associated with menu expansion and platform development. Dr. Kayyem will step down from his position as CEO. Concurrently, Christopher Gleeson, former President and CEO of Ventana Medical Systems and current Chairman of GenMark, has been appointed to the position of CEO, which he plans to fill on an interim basis. GenMark will immediately commence the search process for a new CEO.
“Our first quarter as a Nasdaq listed company saw strong growth, particularly in reagent test revenues. In addition, placements of our XT-8 system exceeded our expectations and we are extremely pleased with the productivity of our new and still growing direct sales force,” commented Christopher Gleeson, Chairman and CEO. Gleeson went on to say, “It has become even clearer to us that relevant menu expansion in an IVD environment, coupled with automated platforms that deliver both high quality and high productivity to our customers, are going to be key drivers of both growth and value, and the appointment of Dr. Kayyem to the CSO role is an integral step in enabling our company to achieve its goals in these areas.”
YEAR TO DATE 2010
Net sales for the six months ended June 30, 2010 were $1.0 million, a 140% increase over the same period in 2009. Reagents test revenues grew 70% year over year while gross margin loss improved significantly from a loss of $1.7 million during 2009 to a loss of $380,000 during the 2010 period. R&D spending increased by 11% and investment in sales force and other commercial activities increased 75%.
INVESTOR CONFERENCE CALL
GenMark will hold a conference call to discuss second quarter 2010 results and the outlook for the full year at 4:30PM EDT today. The conference call and webcast can be accessed live through the company’s website under the Investor Relations section. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number “87984618” approximately five minutes prior to the start time.
ABOUT GENMARK
GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMark’s XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed four diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.
SAFE HARBOR STATEMENT
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding continued growth in sales of our diagnostic tests, the expansion of our diagnostic test menu, and the continued development of our technology, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the “Risk Factors” in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Financial Statements
GENMARK DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| As of June 30, 2010 | As of December 31, 2009 | |||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 29,603,649 | $ | 16,482,818 | ||||
Accounts receivable | 437,457 | 169,842 | ||||||
Inventories | 330,453 | 136,967 | ||||||
Other current assets | 868,297 | 992,181 | ||||||
Total current assets | 31,239,856 | 17,781,808 | ||||||
Property and equipment-net | 1,779,418 | 1,381,618 | ||||||
Intangible assets-net of accumulated amortization | 101,854 | 170,051 | ||||||
Other long-term assets | 55,355 | |||||||
Total assets | $ | 33,176,483 | $ | 19,333,477 | ||||
Current liabilities | ||||||||
Accounts payable | $ | 915,149 | $ | 1,504,905 | ||||
Accrued compensation | 1,277,483 | 822,388 | ||||||
Other current liabilities | 1,439,335 | 886,032 | ||||||
Total current liabilities | 3,631,967 | 3,213,325 | ||||||
Long-term liabilities | ||||||||
Other non-current liabilities | 814,512 | 795,334 | ||||||
Total liabilities | 4,446,479 | 4,008,659 | ||||||
Stockholders’ equity | ||||||||
Ordinary shares, £0.23 ($0.3634 as of December 31, 2009) par value; -0- and 7,101,928 shares issued and outstanding as of June 30, 2010 and December 31, 2009, respectively | — | 2,573,857 | ||||||
Deferred shares, £0.0099 ($0.01709 as of December 31, 2009) par value; -0- and 689,478,300 shares issued and outstanding as of June 30, 2010 and December 31, 2009, respectively | 11,780,709 | |||||||
Common stock, $.0001 par value; 100,000,000 authorized; 11,723,512 and -0- issued and outstanding as of June 30, 2010 and December 31, 2009, respectively | 1,172 | |||||||
Preferred stock, $0.0001 par value; 5,000,000 authorized, none issued | — | |||||||
Additional paid-in capital | 165,254,942 | 127,475,450 | ||||||
Accumulated deficit | (136,076,154 | ) | (126,089,889 | ) | ||||
Accumulated other comprehensive loss | (449,956 | ) | (415,309 | ) | ||||
Total stockholders’ equity | 28,730,004 | 15,324,818 | ||||||
Total liabilities and stockholders’ equity | $ | 33,176,483 | $ | 19,333,477 | ||||
GENMARK DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2010 | 2009 | 2010 | 2009 | |||||||||||||
Revenue | ||||||||||||||||
Product sales | $ | 523,197 | 231,068 | $ | 907,446 | $ | 408,979 | |||||||||
License and other revenue | 127,515 | 17,500 | 142,530 | 27,889 | ||||||||||||
Total revenue | 650,712 | 248,568 | 1,049,976 | 436,868 | ||||||||||||
Cost of sales | 862,285 | 732,281 | 1,429,681 | 2,106,842 | ||||||||||||
Gross loss | (211,573 | ) | (483,713 | ) | (379,705 | ) | (1,669,974 | ) | ||||||||
Operating expenses | ||||||||||||||||
Sales and marketing | 1,203,672 | 741,461 | 2,261,957 | 1,295,414 | ||||||||||||
Research and development | 1,723,991 | 1,432,567 | 3,177,750 | 2,862,915 | ||||||||||||
General and administrative | 2,002,272 | 1,605,900 | 4,169,536 | 3,063,334 | ||||||||||||
Total operating expenses | 4,929,935 | 3,779,928 | 9,609,243 | 7,221,663 | ||||||||||||
Loss from operations | (5,141,508 | ) | (4,263,641 | ) | (9,988,948 | ) | (8,891,637 | ) | ||||||||
Other income | ||||||||||||||||
Foreign exchange (loss) gain | (7,196 | ) | (1,110 | ) | 124,570 | |||||||||||
Interest income | 4,172 | 3,599 | 8,826 | 26,296 | ||||||||||||
Total other income | 4,172 | (3,597 | ) | 7,716 | 150,866 | |||||||||||
Loss before income taxes | (5,137,336 | ) | (4,267,238 | ) | (9,981,232 | ) | (8,740,771 | ) | ||||||||
Benefit (provision) for income taxes | — | — | (5,049 | ) | 59,089 | |||||||||||
Net loss | $ | (5,137,336 | ) | $ | (4,267,238 | ) | $ | (9,986,281 | ) | $ | (8,681,682 | ) | ||||
Net loss per share, basic and diluted | $ | (0.60 | ) | $ | (1.08 | ) | $ | (1.28 | ) | $ | (2.22 | ) | ||||
Weighted average number of shares outstanding | 8,538,897 | 3,951,671 | 7,830,346 | 3,914,319 | ||||||||||||
Condensed Consolidated statements of comprehensive loss three and six months ended June 30, 2010 and 2009 | ||||||||||||||||
Net loss | $ | (5,137,336 | ) | $ | (4,267,238 | ) | $ | (9,986,281 | ) | $ | (8,681,682 | ) | ||||
Foreign currency translation adjustment | — | (315,934 | ) | (34,647 | ) | (530,673 | ) | |||||||||
Comprehensive loss | $ | (5,137,336 | ) | $ | (4,583,172 | ) | $ | (10,020,928 | ) | $ | (9,212,355 | ) | ||||
GENMARK DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| Six Months Ended June 30, | ||||||||
| 2010 | 2009 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (9,986,281 | ) | $ | (8,681,682 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 468,398 | 717,640 | ||||||
Loss from disposal of property and equipment | — | (10,000 | ) | |||||
Impairment losses | — | 549,148 | ||||||
Share-based compensation | 812,302 | 95,957 | ||||||
Changes in operating assets and liabilities: | ||||||||
Trade accounts receivable | (267,615 | ) | (2,102 | ) | ||||
Inventories | (127,679 | ) | 102,125 | |||||
Other current assets | (224,720 | ) | 951,118 | |||||
Accounts payable | (802,141 | ) | (766,314 | ) | ||||
Accrued compensation | 455,095 | (67,317 | ) | |||||
Accrued and other liabilities | 563,488 | (538,400 | ) | |||||
Net cash used in operating activities | (9,109,154 | ) | (7,649,827 | ) | ||||
Investing activities: | ||||||||
Proceeds from the sale of property and equipment and intangible assets | 10,000 | |||||||
Purchases of property and equipment | (574,828 | ) | (446,511 | ) | ||||
Net cash used in investing activities | (574,828 | ) | (436,511 | ) | ||||
Financing activities: | ||||||||
Proceeds from issuance of ordinary shares and common stock, net of offering expenses | 27,600,000 | 8,462,976 | ||||||
Costs incurred in conjunction with initial public offering | (4,752,986 | ) | ||||||
Proceeds from stock option exercises | 4,734 | — | ||||||
Net cash provided by financing activities | 22,851,748 | 8,462,976 | ||||||
Net increase in cash and cash equivalents | 13,167,766 | 376,638 | ||||||
Cash and cash equivalents at beginning of period | 16,482,818 | 8,822,458 | ||||||
Effect of foreign exchange rate changes | (46,935 | ) | (377,306 | ) | ||||
Cash and cash equivalents at end of period | $ | 29,603,649 | $ | 8,821,790 | ||||
Supplemental cash flow disclosures: | ||||||||
Cash received (paid) for income taxes | $ | (5,049 | ) | $ | 202,155 | |||
Cash received for interest | $ | 8,826 | $ | 26,296 | ||||
Noncash investing and financing activities: | ||||||||
Reclassification of deposits on systems in other current assets, and inventory to property and equipment in 2010 and 2009, respectively | 288,962 | 256,909 | ||||||
IPO Costs incurred but not paid | 237,953 | |||||||
Transfer of systems from property and equipment into inventory | 65,806 | |||||||
Please refer to the Company’s SEC filings for more information.
Contacts
GenMark Diagnostics, Inc
Steven Kemper
Chief Financial Officer and Treasurer
760-448-4303
Source: GenMark Diagnostics, Inc
